Hypertension segregates within families, indicating that genetic factors explain some of the variance in the risk of developing the disease; however, even with major advances in genotyping technologies facilitating the discovery of multiple genetic risk markers for cardiovascular and metabolic diseases, little progress has been made in defining the genetic defects that cause elevations in blood pressure. Several plausible explanations exist for this apparent paradox, one of which is that the risk conveyed by genes involved in the development of hypertension is context dependent. This notion is supported by a growing number of published animal and human studies, although none has yet provided unequivocal evidence that genetic and environmental factors interact to influence the risk of primary hypertension in humans. In this review, an assumption is made that common genetic variation contributes meaningfully to the development of primary hypertension. The review focuses on (i) several methodological limitations of genetic association studies and (ii) the roles that geneenvironment interactions might play in the development of primary hypertension. The proceeding sections of the review examine the design features necessary for future studies to adequately test the hypothesis that genes for primary hypertension act in a context-dependent manner. Finally, an outline of how knowledge of gene-environment interactions might be used to optimize the prevention or treatment of primary hypertension is provided.
Introduction
The past 3 years have witnessed unprecedented advances in our understanding of the genetic basis of complex disease. In type II diabetes, for example, only two bonafide risk genotypes had been discovered before 2006; 1,2 since then, more than 16 robustly confirmed risk genotypes have been unearthed. 3 The genetics of dyslipidaemia is even more impressive, with more than 20 loci confirmed to be associated with lipid traits at the time of writing this review. [4] [5] [6] The factor underlying these successes has been the evolution of a high-throughput genotyping method known as the genome-wide association study (GWAS), which has enabled researchers to genotype 4300 000 variants in large population-based cohorts and case-control studies. Although molecular geneticists who focused on complex metabolic diseases have tried to pick the lock of the human genome for more than a decade with relatively little success, the GWAS has, through brute force, facilitated the discovery of many promising genetic risk markers for numerous complex traits; unfortunately, the GWAS has not so far proven successful for elucidating the genetic basis of hypertension. 7 Several plausible explanations exist for why there has been such difficulty in identifying genetic risk factors for primary hypertension, not least that the trait may not be genetically determined. However, high blood pressure segregates within families, with heritability estimates (h 2 ) for systolic and diastolic blood pressures ranging between 40-70 and 20-60%, respectively. 8 Although non-genetic factors are heritable, 9 heritability estimates of this level suggest that additive genetic effects underlie the between-individual variation in blood pressure. Hence, in this review, an assumption is made that genetic risk factors for primary hypertension exist, and the putative factors that could inhibit the detection of genetic effects are discussed (see Table 1 ). To this end, a cursory overview of the roles played by measurement error, bias and confounding is provided. Thereafter, the possible roles of gene-gene and gene-environment interactions on hypertension risk are discussed. The final section of this review focuses on the putative clinical implications of discovering gene-environment interactions.
Methodological limitations to studying the genetics of human hypertension
Phenotype ascertainment and quantification In clinical practice, it is often the case that disease traits are defined in categories. Such is the case with blood pressure, weight, blood glucose levels and blood lipid levels, to name but a few examples. One intriguing, yet often overlooked detail is that rarely do the thresholds used to define the categorical disease traits correspond with marked elevations in the risk of developing the end point they are intended to predict. Indeed, for most biological cardiovascular risk factors including blood pressure, the relationships between the trait and hard end points such as myocardial infarction, stroke or vascular death are often linear, 10, 11 indicating that the trait would be most effectively described by expressing it in continuous terms. A clinician's need to succinctly convey to a patient the results of diagnostic testing might justify the use of biologically artificial thresholds in the clinic. However, in research, the caveat to using such thresholds is that they generally increase the risk of type II error. 12 In other words, with all else being equal, a study in which a trait such as blood pressure is expressed in categories (that is, hypertension vs normotension) will have lower statistical power to detect an association compared with a study in which blood pressure is expressed as a continuous trait (that is, in mm Hg).
One plausible argument for the use of a categorical hypertension variable in genetics studies is that people with hypertension are often treated with drugs to lower their blood pressure. Thus, if a gene variant is strongly associated with blood pressure, and those who carry the high risk genotypes are successfully medicated, the ability to detect an association between the variant and blood pressure could be reduced (see Figure 1 ). To overcome this limitation, hypertension is often defined as a blood pressure above a specific threshold and/or treatment with blood pressure-lowering drugs. However, there are more effective approaches to dealing with the problem of confounding by medication. One is to define blood pressure as a continuous dependent variable and to include as a covariate, a variable defining the amount and type of blood pressure medication used by each participant in the study. 
Regression dilution
Caused by the deviation in the observed value of a measured trait from its true 'usual' value. Traits such as blood pressure that are highly variable within an individual are particularly prone to regression dilution (sometimes termed 'attenuation'). For these traits, a single measurement of the trait is unlikely to represent its true usual value. Achieving an accurate estimate requires that repeated measurements of the trait are obtained and averaged. An example of a trait that is not prone to regression dilution is height 2 Medication bias Occurs when effective treatments are used more frequently in persons carrying the high-risk alleles for a disease trait than in those who carry the low-risk alleles. Medication bias can potentially mask (or even reverse) the association between a genotype and the disease trait 3 Population stratification A type of confounding that occurs in genetic association studies when the frequencies of specific alleles and a disease trait differ between subgroups of the cohort being studied. Unless an accurate marker of these subgroups (such as ethnicity) is available as a covariate in analysis, it is possible that a genetic association with a disease trait could be falsely detected in pooled analyses. In genetic association studies involving different ethnic groups, it is common that data from these groups are meta-analysed to help overcome population stratification 4 Survival bias In ageing populations, those who carry the high-risk alleles for diseases such as hypertension may die sooner than those carrying the low-risk alleles. This phenomenon could potentially lead to a decline in the high-risk allele frequencies within the population and changes in the characteristics of the subgroup carrying the high-risk allele(s).
As the penetrance of most genotypes for complex traits is less than complete, those who survive in the high-risk genotype group may be selectively protected from the disease trait and its adverse consequences (for example, death) 5 Gene-gene interaction Interactions relate to the dependency of one exposure on another exposure for it to exert its effects. A statistical interaction is defined by the departure from additivity when the combined effects of the two exposures on an outcome are determined. When the exposures are both genes, the term 'epistasis' is often applied. The concept arises when the product of one gene (designated the modifier gene) either promotes or inhibits the transcription or translation of another gene 6 Geneenvironment interaction Gene-environment interactions occur when the magnitude of the effect of an environmental exposure on the disease trait differs in magnitude by genotypes at a specific locus. As with epistasis, the interaction effect reflects the dependency of an environmental exposure on a genotype or vice versa. The word 'environment' is used liberally in this context to mean any factor to which the cell is exposed that cannot be directly classified as genetic 7 Common diseaserare variants Although many subscribe to the view that most complex disease traits result from the collective action of a few common disease-predisposing alleles, it is likely that the combination of rarer alleles also influences the development of disease traits. The tendency of the field to focus on common variants is partly owing to the difficulties of studying to very large cohorts, which are necessary to study the effects of rare alleles with small effects Alternatively, only people with blood pressures below the treatment thresholds could be included in the study. Although this latter approach would avoid confounding by medication, one would require a much larger cohort to successfully identify genetic associations owing to the narrower range of blood pressures being studied. This approach would also be unsuccessful if the association between genotype and blood pressure is non-linear, with the association emerging at higher blood pressures, which may be true for some monogenic causes of the disease.
An approach that is often considered optimal in epidemiological settings in which disease treatment or labelling might cause confounding (for example, people tend to report lifestyle behaviours differently after they have been diagnosed with a disease than before the diagnosis) is termed the nested casecontrol design. Using this design, initially nondiseased participants who have undergone detailed baseline examinations in a prospective cohort study are selected based on their follow-up status as either cases or controls. The appeal of this approach is that disease labelling occurs after the baseline measurements have been obtained and is hence unlikely to influence the reporting of behaviours. The caveat to the nested case-control study is that a large initial starting sample is often required, with a longenough follow-up duration to allow a sufficient number of incident cases to accrue. As an example, we recently embarked on a nested case-control study that aims to explore interactions between genetic variants and lifestyle factors on type II diabetes risk (www.inter-act.eu). To derive an appropriately powered study sample of 12 000 case-control pairs, we began with a cohort of almost 350 000 non-diseased individuals who were followed up for an average of roughly 10 years. Thus, although the nested case-control design is considered by many to be the optional paradigm for studying gene-lifestyle interactions, the cost of such studies is much greater than conventional crosssectional designs.
A person's blood pressure will vary greatly across the day, with moment-to-moment fluctuations occurring in response to physiological and psychological stressors, as well as circadian patterns of variation. 13 Thus, when a single measure of blood pressure is taken, it is unlikely to represent the true average blood pressure for that individual. Variations of this nature inhibit the ability to detect genetic associations because the outcome is measured with error, a concept sometimes termed regression to the mean or regression dilution effect.
14 To overcome this limitation, requires repeated or (ideally) continuous blood pressure monitoring for a week or more to acquire a representative range of usual blood pressures for each participant in the study.
Confounding the conventional definition of confounding stipulates that the confounding factor is able to causally affect the outcome and the putative exposure. 15 Confounding in genetic association studies is generally much less of a problem than in non-genetic association studies, owing to the salient nature of a genotype-by and large, a person's genetic code remains unchanged throughout life. Factors such as medication, smoking, diet, physical activity or obesity cannot causally affect one's genotype; hence genotypes are more resilient to confounding than many other biologic exposure variables. However, there are ways in which confounding can occur in genetic association studies, which include survival bias, population stratification and treatment bias (as described above). Survivor bias occurs when death rates differ sufficiently by genotype. If a genotype is associated with a disease that eventually causes death, it is possible that in populations in which death from that disease is common, the prevalence of the high-risk genotypes will eventually decline in the living fraction of the population. Hence, as illustrated in Figure 2 , if the relationship between a genotype and mortality is sufficiently strong, it is possible that within the living fraction of the population, the association between the genotype and disease trait may contrast the true causal relationship. As many blood pressure genetics studies are undertaken in older populations, age should almost always be considered as a putative confounding factor.
A second factor that can cause confounding in genetic association studies, termed population stratification, relates to the effect of simultaneously studying several populations with diverse genetic backgrounds in which the frequencies of a putative risk genotype and of the disease trait are coincidently higher in one or more of the sub-populations. In this scenario, an association between a gene variant and disease trait may be observed purely by chance, unless adequate steps are taken to control for the genetic substructure of the populations included in the study. An additional well-recognized way in which the relationship between a gene variant and a disease trait might be falsely observed involves linkage disequilibrium (LD) between pairs of genotypes. LD defines the extent to which different genotypes are inherited together and is usually expressed as the square of the correlation coefficient for a pair of genotypes (r 2 ) or as D 0 (see Slatkin 16 for description of LD). Thus, non-causal relationships are often observed between gene variants and disease traits owing to the variant being in high LD with the (usually unobserved) functional variant. Providing the LD between genetic variants is sufficiently high, the observed variant serves as an excellent proxy (or tag) for the true functional variant (at least within the specific ethnic group being studied). Although information about the tagging locus can be sufficient for confirming the presence of a genetic association with a trait and for predicting the development of the trait, it is inadequate if the objective is to intervene, for example with drugs, by modulating the specific molecular defect causing the disease. Thus, once the associations with non-functional variants are confirmed, considerable efforts are often invested in identifying the linked causal variants (a method known as fine mapping). In most examples of genotypes associated with cardiovascular traits, the causal variants remain unresolved. Given that in most cases, the level of LD between the observed risk genotype and the true unobserved functional genotype is unlikely to be perfect, a proportion of those carrying the observed genotype will not, by definition, carry the true functional locus; by consequence, the estimated effect of the genotype on disease risk will be diluted, as will the power to detect the association between the genotype and the disease trait. Thus, the identification of diseasecausing (as opposed to disease-associated) genotypes will generally enhance the detection of genotype-disease associations and gene-environment interactions. Identifying genes for primary hypertension PW Franks
Publication bias
Historically, journals have been more willing to publish statistically significant genetic association studies and have shied away from publishing studies with negative findings, even if those studies have been well designed. By consequence, the literature is swamped with the reports of genetic associations that have not been adequately replicated. One method of summarizing the literature is to perform meta-analyses of published genetics data. Using this approach, it is also possible to quantify the effects of publication bias. 17 In the absence of publication bias, one should observe an even distribution of the individual study's effect estimates around the summary effect for all studies. A substantial deviation from this distribution provides evidence that studies with specific effects have been favoured for publication. A major problem associated with publication bias is that it becomes difficult to distinguish between true-and false-positive reports, thus hindering progress in defining the genetic basis of many diseases. One of the reasons the GWAS has proven so successful is that the method is agnostic to prior evidence concerning the role of specific genes in disease (that is, it is a hypothesis-free approach).
Context-dependent genetic effects on hypertension risk
Gene-gene interaction The common disease-common variant hypothesis pivots on the notion that most common diseases manifest from the accumulation of multiple common genetic risk alleles, each with relatively small effects. 18, 19 Type II diabetes, 3 dyslipidaemia, 4-6 linear growth 20, 21 and prostate cancer, [22] [23] [24] for example, appear to result from a multitude of accumulated genetic defects. It seems equally plausible that the genetic basis to hypertension also involves a large number of relatively common variants, each with small contributory effects. Although it is likely that gene-gene interactions are aetiologically relevant for most complex disease traits, little is known of how such interactions manifest. Blood pressure is a biologically complex trait with numerous regulatory feedback mechanisms; thus, gene-gene interactions are likely to be especially important entities in blood pressure regulation. One reason why little is known about the role of gene-gene interactions is that studying them is exceptionally difficult; owing to the higher number of statistical comparisons inherent in interaction tests and because they are often undertaken as secondary analyses, studies of interaction are prone to higher false discovery rates than conventional genetic association studies. Thus, the detection and confirmation of interactions requires specifically designed studies, of which few if any presently exist.
Gene-environment interaction
A gene-environment interaction occurs when the magnitude of the relationship between a genotype and a phenotype is dependent on the environmental context. The word 'environment' is used liberally to define almost every non-genetic factor to which cells are exposed. The principle of interaction, be it gene-gene or gene-environment interaction, relates to the dependency between the genotype and another factor. Although interactions can be antagonistic, most published examples of gene-environment interactions for blood pressure involve synergistic effects, where the combined effects are greater than the sum of the components. Depending on how the interaction effect manifests, it is possible for it to mask main genetic effects. Figure 3 provides an illustration of how this might occur. In this example, we examined the time-dependent effects of an 11BHSD1 genotype on blood pressure levels in adults born between 1940 and 1980. 25 Although in earlier birth cohorts, carriers of the minor homozygous genotype (represented by the black bars) have the highest blood pressures, the effect reverses with time, such that in later birth cohorts, the genotype conveys an apparently protective effect. Although in this example, a nominal main effect of the genotype was detectable, it was partially obscured by the interaction. Thus, it is likely that where genetic effects are context dependent, the detection of genotype-disease associations will be concealed.
A more likely mode of interaction is the one in which the genetic effect is weak at one end of the environmental spectrum and becoming progressively stronger as the environment changes. Although main genetic effects may be detectable in the presence of such interactions, it may be possible to enhance the detection of genetic effects by modelling their environmental dependency (see Figure 4 ). This has particular relevance when considering the roles of genetics in disease risk prediction, both for the enhancement of predictive power 26 and when considering how genetic risk might be attenuated (see below for further discussion of these points).
Typically, researchers studying gene-environment interactions in observational studies of hypertension have focused on dietary salt consumption (see Beeks et al. 27 for a systematic review), although others have also examined genetic interactions with alcohol consumption, 28 cigarette smoking, 29 drug agonists, 30, 31 or acute or chronic bouts of physical exercise. [32] [33] [34] [35] [36] [37] [38] [39] [40] Some, but not all, of these studies emanate from clinical trials of exercise, diet or drug treatment interventions on blood pressure regulation. The most widely studied gene in this context is the angiotensinogen I-converting enzyme gene (ACE). The enzyme encoded by ACE facilitates the conversion of angiotensin I into a physiologically active peptide angiotensin II. The latter regulates blood pressure and fluid-electrolyte homoeostasis through the stimulation of aldosterone and is active within the renin-angiotensin system. Various ACE polymorphisms have been studied, including the insertion/deletion (I/D) variant and the M235T missense variant. Studies examining the modifying roles of ACE genotypes on blood pressure response to exercise have focused primarily on the effects of acute exercise often in relatively small samples. [32] [33] [34] [35] [36] [37] [38] [39] At least two medium-to long-term clinical trials from North America 37 and Finland 40 have reported on the association between ACE genotypes and blood pressure responses to long-term aerobic exercise training. In the North American HERITAGE study, Rankinen and colleagues examined the blood pressure response by ACE I/D and M235T genotypes to an exercise stress test before and after 20 weeks of aerobic exercise training. 37 Both genotypes were associated with baseline and post-training blood pressure responses to an exercise stress test in men. No associations were evident in women. In the Finnish study, people randomized to the exercise intervention and homozygous for the M235 allele conferred reductions in sitting systolic blood pressure of around 1.0 mm Hg 6 years after randomization, which contrasted the 14.6 mm Hg increase in blood pressure in M235 allele homozygotes assigned to the control group. 40 Although the majority of studies have reported statistically significant associations between ACE genotypes and blood pressure response to exercise, these studies are generally small in size, have involved uncorrected multiple hypothesis testing and, by consequence, are likely to be underpowered and prone to false discovery. Thus, it is probable that equivalently designed studies that found no evidence of association exist but remain unpublished. If this is true, the summary genetic effects would be upwardly biased and an accurate appraisal of the role of ACE genotype-exercise interactions in blood pressure regulation would be very difficult to achieve.
Several studies on gene-environment interaction have focused on genotypes in the endothelial nitric Figure 4 Illustration of how genetic effects might be more detectable within specific environmental settings. In this example, the genetic effect size (and power to detect) is greatest to the right of the lifestyle distribution, where lifestyles are least unhealthy.
Identifying genes for primary hypertension PW Franks oxide synthase gene (NOS3). Nitric oxide (NO), a derivative of NO synthase (NOS), is continuously synthesized from endothelial cells and myocytes during the metabolism of energy and is present throughout the body. NO is involved in many inter-and intracellular processes, but in the context of blood pressure regulation, it acts primarily as a vasodilator. Three isoforms of the gene encoding NOS have been identified-neuronal (nNOS; encoded by the NOS1 gene), inducible (iNOS; encoded by the NOS2 gene) and endothelial (eNOS; encoded by the NOS3 gene)-and are known to be upregulated following aerobic exercise. 41 The effect of muscle contraction, a key component of aerobic exercise, on NO production is marked with elevations in the range of 50-200%. 42 In addition to the well-described acute effects of muscle contraction on NO production, exercise training has also been shown in rats to induce chronic adaptations in NOS1 and NOS3 gene expression. 43 The main mechanisms by which exercise-induced NO synthesis affects vessel compliance involve vasodilatation, capillary recruitment and hyperaemia. 44 In animals partially lacking the Nos3 gene, these mechanisms are severely disrupted and result in hypertension, hyperinsulinaemia and dyslipidaemia. 45 We and others have reported on the interaction between NOS3 genotypes and physical activity on hypertension risk. [46] [47] [48] The first published study of NOS3 genotypes, exercise and blood pressure emanates from the North American HERITAGE study. 48 In this report, which focused on the same data set and phenotypes described above (study by Rankinen et al. 37 ), the authors observed greater reductions in exercising blood pressure following a 20-week exercise training programme in carriers of the major Glu allele at the NOS3 Glu298Asp genotype. In Japanese adults, a gene by physical activity interaction was reported on systolic blood pressure levels for a variant in intron 4 of the NOS3 gene, which was characterized by a stronger inverse relationship between the genotype and blood pressure in physically inactive compared with active individuals. 47 In our study, 46 we genotyped polymorphisms that captured all of the common NOS3 variations evident in European whites in a sample of 726 ethnically homogeneous white adults from the East Anglia region of the United Kingdom. Physical activity was measured objectively using free-living heart-rate monitoring, individually calibrated to energy expenditure directly assessed during a submaximal incremental-load exercise stress test. 49 We observed statistical interactions between the NOS3 IVS25 þ 15 genotype and physical activity on blood pressure levels, whereby the relationship between physical activity and blood pressure was statistically stronger in common allele homozygotes (GG genotype) compared with carriers of the minor 'A' allele.
Two additional studies have focused on the interactions between NOS3 genotypes and salt intake. 50, 51 In one study of Venezuelan adults, 51 the Glu298Asp and intron 4 SNPs were studied. The Glu298T polymorphism was not associated with NO production or salt sensitivity. However, the intron 4 SNP was associated with lower levels of NO metabolites, a significantly higher prevalence of salt-sensitive hypertension and greater reductions in blood pressure following salt restriction (9.0 vs 4.8 mm Hg, Po0.05). The second study in 28 obese hypertensive older adults from the United States, the associations between the NOS3 T-786C genotype and blood pressure response to 8 days of low (20 mEq)-and high (200 mEq)-salt diets were assessed. Carriers of the minor C allele had a significantly greater increase in diastolic blood pressure and a significant decline in both renal plasma flow (P ¼ 0.007) and glomerular filtration rate (P ¼ 0.029) following salt loading compared with the TT genotype group. Salt loading also increases plasma NO metabolite levels in the TT genotype group, whereas no change was observed in the minor C allele carriers.
Interpreting the evidence of gene-environment interactions Notwithstanding the growing number of publications describing examples of gene-environment interactions, the reality is that all existing studies are grossly underpowered to detect interaction effects on blood pressure traits, and many have probably emerged as a result of multiple, yet unreported, statistical comparisons. Hence, it is important to remain cautious when interpreting the value of reports of interaction and to give the most credibility to the examples that have been consistently replicated; the collections of studies with the most value are those that have examined the same phenotype and genetic locus, characterized the environmental exposure in a comparable manner and have used similar statistical approaches to test for interaction. Ideally, the data from these studies would then be appropriately meta-analysed. In the absence of such studies, it is possible that the recent trend to combine large collections of materials for blood pressure genetics research will allow large-scale investigations of gene-environment interaction to be pursued. Providing robust examples of gene-environment interactions in blood pressure traits will likely require cohorts comprising tens of thousands of individuals. If the GWAS approach is to be used, the required sample sizes may be an order of magnitude larger owing to the need for more conservative statistical thresholds. However, most of the existing large genetics studies lack adequate data on environmental exposures; by consequence, it may be necessary for cohort collections with the specific characteristics needed to address research question about gene-environment interactions to be collated.
Gene-drug interactions
Although this review has focused primarily on the roles of gene-gene and gene-lifestyle interactions in the aetiology of hypertension, it would be remiss not to mention the exciting concept of gene-drug interaction. Examples exist for several complex diseases in addition to hypertension in which the effectiveness of prescription drugs on the disease phenotype apparently differs between genotypes at specific loci. For example, two studies have examined the effects of vascular dynamics in response to treatment with drug agonists. The first focused on the effects of angiotensin II infusion (3 ng kg À1 min À1 ) on renal plasma flow and renal arterial resistance in family history-positive (n ¼ 34, hypertensive; n ¼ 57, normotensive) and -negative (n ¼ 29, normotensive) adults carrying different genotypes at the methionine 2354 threonine locus in the angiotensinogen gene (AGT). 31 The authors reported blunted renal response in minor threonine allele homozygotes. Elsewhere, the modifying effects of the Arg16Gly polymorphism at the b2 adrenergic receptor gene (ADRB2) on treatment with salbutamol (a selective ADRB2 agonist) were studied in 57 normotensive adult male individuals. 30 Resting blood pressure was significantly higher, and salbutamol-induced vasodilation was reduced in Gly16 homozygotes compared with Arg16 homozygotes, despite the increased sympathetic counter-regulation in Arg16 homozygotes. We have earlier reported differential effects of metformin on diabetes incidence in carriers and non-carriers of the risk allele at the E23K locus at the KCNJ11 gene. 52 We have also shown that the weight-inducing effects of troglitazone (a thiazoladinedione class of drug well known to induce weight gain) are confined largely to the carriers of the minor allele at the PPARG Pro12Ala genotype. 53 Possibly the most accepted, although indirect, example of gene-drug interaction is for the BiDil drug, used to treat heart failure, which the Food and Drug Administration has specifically approved for use in African Americans owing to its apparently pronounced effects in this ethnic group. 54, 55 Is there any clinical relevance to knowing how genetic and environmental factors interact?
An often-used argument to justify research on human genetics is that identifying genetic associations with disease traits will elucidate the underlying molecular pathways and lead to the development of pharmacotherapies that can be used for prevention or treatment. Although examples exist for monogenic diseases in which this has proven true, the discovery of genetic associations for complex disease traits has rarely led to the development of successful drug targets.
An alternative approach to developing specific drug targets is to identify treatments that are shown in clinical trials to modify genetic risk effects. Figure 5 shows the interaction between the G62A variant at the G-protein-coupled receptor 10 (GPR10) gene and the physical activity on blood pressure in 700 middle-aged UK whites; 56 these data indicate that the association between physical activity and blood pressure is dependent on the genotype carried at the G62A locus. In common 'G' allele homozygotes in this study, a strong inverse relationship was observed between physical activity and blood pressure. This is consistent with the effects of exercise on blood pressure in numerous intervention studies. 57 However, there was no evidence of association between physical activity and blood pressure in those carrying the minor 'A' allele (approximately 40% of the population). Importantly, interactions of this nature would need to be shown within clinical trials before they could be used to inform treatment guidelines. However, if supported by clinical trials, such an evidence might be used to identify people whose blood pressure is more or less responsive to physical activity. In 'responsive' individuals, an additional support might be offered to enhance and help maintain increased physical activity levels. Although in 'non-responsive' individuals, physical activity should be promoted, given the numerous other health-related gains of exercise, 58 but it might also be prudent to promote other strategies for blood pressure reduction to ensure optimal care within this subgroup.
Summary
When placed in context with the major advances in the genetics of other complex cardiovascular disease traits, attempts to elucidate the genetic basis of human hypertension have, thus far, proven unsuccessful. The frustratingly slow progress in hypertension genetics has prompted many to consider what factors differentiate blood pressure from other aetiologically related traits. In this review, several of these factors are discussed, including the effects of gene-gene and gene-environment interactions. The nature of this discussion is of course rather speculative, as no sufficiently powered studies have been reported on these concepts, and the quality of replication efforts accompanying published examples of interaction from underpowered studies is insufficient to conclude on the validity of these findings. However, several very large blood pressure genetics consortiums are emerging, and it is likely that if common genetic variation does indeed contribute to blood pressure variation, these consortiums are likely to identify the culpable genetic defects. A logical progression will be to construct even larger and better-characterized data sets suitable for studying gene-gene and gene-environment interactions. Although not covered in this review, two additional features of future genetics studies of blood pressure will likely include epigenetics (a concept similar in principle to gene-environment interaction but studied at a cellular level) and the search for rare risk variants involved in blood pressure regulation; typically, genome-wide scans have focused on common variants, with minor allele frequencies above 5%. However, there is growing recognition that less-frequent variants are also likely to be important in the development of common complex diseases. Finally, there may be types of genetic variation other than the conventionally studied single-nucleotide polymorphisms that contribute to the regulation of blood pressure, such as copy number variations, which are yet to be studied comprehensively.
In conclusion, although healthy skepticism is an important facet of science, there is a great deal to be performed before genetic variation can be excluded as an important risk factor for human hypertension. If, in the process of furthering this study, genes for hypertension emerge, it will be important to have in mind what can be done with this information to help reduce the burden of hypertension within the population. The concept of gene-environment interaction is appealing in this context, not least because it provides a paradigm through which genetic risk can be modulated using currently available modes of clinical intervention.
